Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement

Value in Health

Volumn 2, Issue 4, 1999, Pages 288-294

  Bergqvist, David ^a   Jönsson, Bengt ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000045767     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1999.24003.x     Document Type: Article

References (19)

1. Bergqvist D, Benoni G, Björgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
2. Planes A, Vochelle N, Mazas F, et al. Risk of deepvenous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
3. Dahl O, Andreasen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-31.
4. Lassen M, Borris L, Andersen BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular weight heparin (Dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res 1998;89:281-7.
5. Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996;93:1548-52.
6. Dunn CJ, Goa KL. Enoxaparin - A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics 1996;10 (2):179-90.
7. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin - A clinical and economic appraisal. Pharmacoeconomics 1995;8(2):91-9.
8. Harrison J, Warwick D, Coast J. Economics of thromboprophylaxis in total hip replacement surgery. Pharmacoeconomics 1997;12:30-41.
9. Lindmarker P, Holmström A. Use of low molecular weight heparin (dalteparin), once daily, for treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395-401.
10. Menzin J, Richner R, Huse D, et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-5.
11. Menzin J, Colditz GA, Regan MM, et al. Cost effectiveness of enoxaparin vs. low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
12. Borris LC, Lassen M, Jensen HP, et al. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery - clinical and economic considerations. Intern J Clin Pharm Ther 1994;32:262-8.
13. Mol WEM, Egberts TCG. Prophylaxis for venous thromboembolism in hip fracture surgery - Total costs and cost effectiveness in The Netherlands. Pharmacoeconomics 1994;5 (1):48-55.
14. Drummond M, Aristides M, Davies L, et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81:1742-6.
15. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;334:724-5.
16. Statistical Yearbook of Sweden 1997, table 55. Stockholm: Statistics Sweden.
17. Levine M, Gent M, Hirsh J. A comparison of low- molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
18. Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
19. Detorunay B, Planes A, Vochelle N, et al. Cost- effectiveness of low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998;13:81-9.